痴呆症临床实践指南:对胆酶抑制剂和记忆剂的建议
Yeshin Kim1, Dong Woo Kang2, Geon Ha Kim3
1Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea.
本指南推用于阿尔茨海默病 (AD) 和其他痴呆症的胆酶抑制剂,以改善认知和功能. 对于中度至重度的AD,也建议使用N-甲基-D-酸盐 (NMDA) 受体对抗剂.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 临床实践指南对于基于证据的痴呆症治疗至关重要.
- 阿尔茨海默病 (AD) 和其他痴呆症需要特定的药理干预措施.
- 胆酶抑制剂和NMDA受体对抗剂是痴呆症管理的关键药物类别.
研究的目的:
- 为痴呆症药物治疗提供基于证据的建议.
- 引导临床医生使用胆酶抑制剂和NMDA受体对抗剂.
- 支持在痴呆症护理中改善患者结果.
主要方法:
- 使用PICO框架进行系统的文献审查.
- 由多学科专家小组对随机对照试验和观察性研究进行评估.
- 使用GRADE方法论对证据质量和强度进行建议评级.
主要成果:
- 强烈建议在阿尔茨海默病中使用胆酶抑制剂来改善认知和日常功能 (中等证据).
- 在血管痴呆症和帕金森病痴呆症中使用胆酶抑制剂的有条件建议;强烈推用于勒维体痴呆症.
- 在中度至重度的AD中,强烈推使用NMDA受体对抗剂 (孟坦丁),以改善认知和功能.
- 两种药物类别均表现出良好的安全性,并具有可控的副作用.
结论:
- 针对痴呆症管理的标准化,基于证据的药理学建议.
- 关于胆酶抑制剂和NMDA受体对抗剂的指导,以支持临床决策.
- 未来的更新将纳入新兴的治疗方法,如用于高级痴呆症护理的粉样蛋白向疗法.
更多相关视频
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
相关概念视频
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Dementia
The progression of dementia is generally gradual....
